List of adverse effects of pazopanib explained

This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence.^{[1] [2] [3] [4] [5]}

Very common

Very common (>10% incidence) adverse effects include:

• Reduced appetite
• Headache
• Taste changes
• High blood pressure^[6]
• Diarrhoea
• Abdominal pain
• Nausea
• Vomiting
• Hair colour change
• Hand-foot syndrome
• Hair loss
• Rash
• Fatigue
• Increased alanine aminotransferase
• Increased aspartate aminotransferase
• Tumour pain^‡
• Myelosuppression^‡[7]
• Stomatitis^‡
• Exfoliative rash^‡
• Skin hyperpigmentation^‡
• Weight loss^‡

Common

Common (1–10% incidence) adverse effects include:

• Tumour pain^†
• Myelosuppression^†[8]
• Underactive thyroid
• Dehydration
• Low level of phosphate in the blood
• Dizziness
• Lethargy
• Paraesthesia
• Peripheral sensory neuropathy
• Blurred vision
• Hot flush
• Venous thromboembolic event
• Flushing
• Nose bleed
• Voice anomalies
• Shortness of breath
• Coughing up blood
• Stomatitis
• Indigestion
• Flatulence
• Abdominal distension
• Dry mouth
• Mouth ulceration
• Hyperbilirubinaemia
• Abnormal liver function
• Hepatotoxicity
• Skin hypopigmentation
• Dry skin
• Itchiness
• Erythema
• Skin depigmentation
• Hyperhidrosis
• Joint pain
• Muscle aches
• Muscle spasms
• Protein in the urine
• Mucosal inflammation
• Weakness
• Oedema
• Chest pain
• Weight loss^†
• Increased blood creatinine
• Lipase increased
• Decreased white blood cell count
• Blood TSH decreased
• Amylase increased
• Gamma-glutamyltransferase increased
• Increased blood pressure
• Increased blood urea
• Abnormal liver function test
• Gingival infection^‡
• Dizziness
• Insomnia
• Peripheral sensory neuropathy
• Heart dysfunction
• Blurred vision
• Low heart rate
• Left ventricular dysfunction
• Bleeding (including haemorrhage)
• High blood sugar
• Low blood sugar

Uncommon

Uncommon (0.1–1% incidence) adverse effects include:

• Torsades de pointes
• Heart failure
• Liver failure
• GI perforation (may be fatal)
• Fistula formation

Rare

Rare (<0.1% incidence) adverse effects include:

• Reversible posterior leucoencephalopathy syndrome

Notes

^† Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma.

^‡ Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.

Notes and References

1. Web site: Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. 27 January 2014.
2. Web site: VOTRIENT (pazopanib hydrochloride) tablet, film coated . DailyMed. GlaxoSmithKline LLC. November 2013. 27 January 2014. PDF.
3. Web site: Votrient : EPAR - Product Information. European Medicines Agency. Glaxo Group Ltd.. 23 January 2014. 27 January 2014. PDF.
4. Web site: Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC). electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. 27 January 2014.
5. Web site: PRODUCT INFORMATION VOTRIENT® TABLETS. TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. 27 January 2014. PDF.
6. Usually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment.
7. This includes leucopenia, thrombocytopenia and neutropenia.
8. This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia.